

# Sotagliflozin

## Catalog No: tcsc1069



### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg



### Specifications

**CAS No:**

1018899-04-1

**Formula:**

$C_{21}H_{25}ClO_5S$

**Pathway:**

Membrane Transporter/Ion Channel

**Target:**

SGLT

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

LX-4211;LP-802034

**Observed Molecular Weight:**


424.94

## Product Description

Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

IC50 & Target: SGLT1/2

***In Vitro:*** LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediated trends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-up single-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly increased glucagon-like peptide-1 and peptide YY levels relative to pretreatment values, probably by delaying SGLT1-mediated intestinal glucose absorption [1]. LX4211-treated mice and SGLT1-/- mice also had increased GLP-1 AUC values, decreased glucose-dependent insulintropic polypeptide (GIP) AUC values, and decreased blood glucose excursions during the 6 hours after a challenge with oral glucose alone [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!